Skip to main content

Table 2 Analysis of overall survival time by clinical factors

From: The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma

Characteristics Patients n (%) OS (months) Univariate analysis Multivariate analysis
P HR (95 % CI) P
Age (years)
  ≥ 75 62 (25) 15.1 0.005 1.35 (0.90–1.99) 0.150
  < 75 184 (75) 24.2 Reference
Sex
 Male 154 (63) 19.1 0.279 1.30 (0.87–1.97) 0.204
 Female 92 (37) 26.2 Reference
Smoking status
 Never 101 (41) 23.8 0.742 0.91 (0.64–1.36) 0.636
 Current or former 145 (59) 19.3 Reference
ECOG PS
 0 or 1 184 (75) 26.5 <0.001 0.42 (0.29–0.62) <0.001
 2–4 62 (25) 8.8 Reference
EGFR status
 Mutated 100 (41) 31.1 0.001 0.41 (0.29–0.57) <0.001
 WT or uninvestigated 146 (59) 16.9 Reference
Stage
 IIIB 26 (11) 43.9 0.016 0.38 (0.21–0.64) <0.001
 IV 220 (89) 20.2 Reference
Serum CEA
 Negative 83 (34) 20.4 0.985 0.79 (0.56–1.11) 0.180
 Positive 163 (66) 21.8 Reference
Serum CYFRA 21-1
 Negative 91 (37) 31.8 <0.001 0.47 (0.32–0.66) <0.001
 Positive 155 (63) 16.9 Reference
Serum CA 19-9
 Negative 170 (69) 26.2 <0.001 0.60 (0.43–0.85) 0.005
 Positive 76 (31) 12.5 Reference
Chemotherapy
 Platinum doublet 170 (69) 25.0 <0.001 0.64 (0.42–0.97) 0.034
 Others 76 (31) 14.2 Reference
  1. CA 19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, CI confidence interval, CYFRA 21-1 cytokeratin 19 fragments, ECOG PS Eastern Cooperative Oncology Group Performance Status, EGFR epidermal growth factor receptor gene, WT wild-type, HR hazard ratio, OS overall survival